# US 2005/0238640 A1 · Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0238640 A1
- Document ID: US20050238640A1
- Status: Published application
- Kind: A1
- Application number: 11/154,465
- Filed: 2005-06-16
- Published: 2005-10-27
- Earliest claimed: 1999-06-25
- Assignees: Genentech, Inc.
- Inventors: Mark Sliwkowski
- Web page: https://patentgrep.com/patent/US20050238640A1

## CPC

- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 33/243: Platinum; Compounds thereof
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 51/10: Antibodies or immunoglobulins; Fragments thereof {, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y10S 424/80: Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
- Y10S 424/801: involving antibody or fragment thereof produced by recombinant dna technology
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.

## Claims

### Claim 1

A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human therapeutically effective amounts of an ErbB2 antibody which blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB-12697) to ErbB2, and an EGFR-targeted drug.

### Claim 2 (depends on 1)

The method of claim 1 wherein the ErbB2 antibody blocks ligand activation of an ErbB receptor.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cancer is characterized by excessive activation of EGFR.

### Claim 4 (depends on 1)

The method of claim 1 wherein the ErbB2 antibody blocks TGF-α activation of mitogen-activated protein kinase (MAPK).

### Claim 5 (depends on 1)

The method of claim 1 wherein the cancer is not characterized by overexpression of ErbB2 receptor.

### Claim 6 (depends on 1)

The method of claim 1 wherein the EGFR-targeted drug comprises an antibody that binds to EGFR.

### Claim 7 (depends on 6)

The method of claim 6 wherein the EGFR antibody is selected from the group consisting of MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509), chimerized 225 (C225), reshaped human 225 (H225), an antibody that binds type II mutant EGFR, and a human antibody that binds EGFR.

### Claim 8 (depends on 1)

The method of claim 1 wherein the EGFR-targeted drug comprises a small molecule that binds to EGFR.

### Claim 9 (depends on 8)

The method of claim 8 wherein the small molecule is selected from the group consisting of ZD1839, CP-358774, and AG1478.

### Claim 10 (depends on 1)

The method of claim 1 wherein the cancer is selected from the group consisting of non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, head and neck cancer, and ovarian cancer.

### Claim 11 (depends on 1)

The method of claim 1 wherein the ErbB2 antibody comprises a humanized form of monoclonal antibody 2C4 (ATCC HB-12697).

### Claim 12 (depends on 11)

The method of claim 11 wherein the humanized antibody comprises variable light (VL) and variable heavy (VH) sequences of SEQ ID Nos. 3 and 4, respectively.

### Claim 13 (depends on 12)

The method of claim 12 wherein the VL and VH sequences are fused to human light and heavy IgG1 (non-A allotype) constant region sequences.

### Claim 14 (depends on 1)

The method of claim 1 wherein the ErbB2 antibody is not conjugated with a cytotoxic agent.

### Claim 15 (depends on 1)

The method of claim 1 further comprising administering to the human a therapeutically effective amount of a third therapeutic agent selected from the group consisting of a second different antibody which binds ErbB2, a chemotherapeutic agent, an anti-angiogenic agent, an anti-hormonal compound, a cardioprotectant, and a cytokine.

### Claim 16 (depends on 1)

The method of claim 1 comprising administering at least one dose of the ErbB2 antibody to the human in an amount from about 0.5 mg/kg to about 10 mg/kg.

### Claim 17 (depends on 16)

The method of claim 16 comprising administering the dose about every three weeks.

### Claim 18

A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human therapeutically effective amounts of an ErbB2 antibody which blocks formation of an ErbB hetero-oligomer, and an EGFR-targeted drug.

### Claim 19 (depends on 18)

The method of claim 18 wherein the ErbB2 antibody is about 50-100% more effective than 4D5 (ATCC CRL 10463) at blocking formation of an ErbB hetero-oligomer.

### Claim 20

A method of treating cancer in a human comprising administering to the human therapeutically effective amounts of rhuMAb 2C4, and an EGFR-targeted drug selected from the group consisting of chimerized 225 (C225), ZD1839, and CP-358774, wherein the cancer is selected from the group consisting of non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, head and neck cancer, and ovarian cancer.
